Trimetrexate Glucuronate
FDA-approved product (injectable, injection), marketed as Neutrexin.
- Registered studies
- 17
- Lab records
- 7
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Trimetrexate Glucuronate. Its therapeutic class is shown instead.
- WHO therapeutic group
- Other agents against amoebiasis and other protozoal diseases
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01AX07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli88.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
17registered studies name this medicine, for any condition. See them below.
Experimental
- E. coli: measured active in 7 of 7 lab records
Show the 7 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Trimetrexate Glucuronate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- IloperidoneExisting use: Psychosis, Schizophrenia45.8% AI-predicted activityagainst E. coli32 registered studies
- Thiethylperazine MalateExisting use: Allergic disease45.8% AI-predicted activityagainst E. coliNo documented evidence found
- Fostamatinib DisodiumExisting use: Autoimmune thrombocytopenic purpura, Hemorrhage, Thrombocytopenia45.7% AI-predicted activityagainst E. coli27 registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more45.7% AI-predicted activityagainst E. coli50+ registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more45.6% AI-predicted activityagainst E. coliNo documented evidence found
- IvabradineExisting use: Angina pectoris, Cardiovascular disease, Congestive heart failure and 1 more45.5% AI-predicted activityagainst E. coli50+ registered studies
- Pimavanserin TartrateExisting use: Hallucinations, Parkinson disease, Psychosis45.4% AI-predicted activityagainst E. coli46 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis45.2% AI-predicted activityagainst E. coli50+ registered studies
- RescinnamineExisting use: Hypertension45.2% AI-predicted activityagainst E. coliNo documented evidence found
- EluxadolineExisting use: Diarrheal disease, Irritable bowel syndrome45.1% AI-predicted activityagainst E. coli10 registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis45.0% AI-predicted activityagainst E. coli7 registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease44.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia
NCT00002317
Registered record
- Registry ID
- NCT00002317
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Trimetrexate glucuronate; Leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionTrimetrexate glucuronate; Leucovorin calciumPhaseNot applicableRegistry statusCompletedA Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)
NCT00002434
Registered record
- Registry ID
- NCT00002434
- Conditions
- Pneumonia, Pneumocystis Carinii; HIV Infections
- Interventions
- Trimetrexate glucuronate; Leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumonia, Pneumocystis Carinii; HIV InfectionsInterventionTrimetrexate glucuronate; Leucovorin calciumPhaseNot applicableRegistry statusCompleted